Jennifer Pietenpol named chief scientific advisor for Susan G. Komen

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Jennifer Pietenpol, executive vice president for research at Vanderbilt University Medical Center and director of Vanderbilt-Ingram Cancer Center, was named a chief scientific advisor for the nonprofit breast cancer organization Susan G. Komen.

She joins George Sledge Jr., professor of Medicine at Stanford University Medical Center, in the CSA role, which includes responsibility for guiding the Komen Scientific Advisory Board.

The scientific advisory board helps guide Komen’s research programs and priorities. Since 2010, Pietenpol has served as a Komen Scholar, an advisory group of distinguished leaders in breast cancer research and advocacy who are chosen for their knowledge and leadership within the scientific, research and advocacy communities, and for their own contributions to breast cancer research.

Pietenpol, the Benjamin F. Byrd Jr. Professor of Oncology at Vanderbilt, is an expert in molecular genetics and triple negative breast cancer. She and her colleagues were the first to identify subtypes of TNBC and are spearheading clinical research trials to determine the best potential therapies for each subtype.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login